Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2018, Vol. 40 ›› Issue (5): 610-616.doi: 10.3881/j.issn.1000-503X.10717

• Comprehensive Treatment of Reducing Weight Forum • Previous Articles     Next Articles

Effectiveness of Laparoscopic Sleeve Gastrectomy in Treating Obesity and Its Co-morbidities

LI Zijian1, YU Jianchun1(), KANG Weiming1, MA Zhiqiang1, YE Xin1, ZHU Huijuan2, YU Kang3, CHEN Wei3, LIU Yanping3, LI Tao4, XIAO Yi5, LUO Jinmei5, ZHANG Shuyang6   

  1. 1 Department of General Surgery, CAMS and PUMC,Beijing 100730,China
    2 Department of Endocrinology, CAMS and PUMC,Beijing 100730,China
    3 Department of Nutrition, CAMS and PUMC,Beijing 100730,China
    4 Department of Psychology, CAMS and PUMC,Beijing 100730,China
    5 Department of Respiratory Medicine, CAMS and PUMC,Beijing 100730,China
    6 Department of Cardiology,PUMC Hospital, CAMS and PUMC,Beijing 100730,China;
  • Received:2018-07-18 Online:2018-10-30 Published:2018-11-07
  • Contact: Jianchun YU


Objective To analyze the effectiveness and safety of laparoscopic sleeve gastrectomy (LSG) in treating obesity and its co-morbidities.Methods The clinical data of obese patients undergoing LSG in Peking Union Medical College Hospital from August 2012 to August 2017 were retrospectively analyzed. Medium-term outcome measures included excess weight loss (%EWL),co-morbidity improvement,and complications.Results Seventy-five obese patients comprising 28 men[ body mass index(BMI):(47.3±7.5)kg/m 2) ] and 47 women [BMI (41.1±7.0) kg/m 2] were enrolled in this analysis. The common co-morbidities were liver dysfunction (53.3%),dyslipidemia (52.0%),obstructive sleep apnea (45.3%),type 2 diabetes mellitus (38.7%),and arterial hypertension (37.3%),which were improved by 75.0%,58.3%,83.3%,75.0% and 58.3% three years after surgery. The mean %EWL at 1,2,and 3 years after surgery was 81.6±34.7,80.9±30.2 and 79.7±30.8,respectively. The proportions of patients achieving successful weight loss were 81.7% (n=49),81.0% (n=34),and 79.3% (n=23) at 1,2,and 3 years (%EWL>50%). Early severe complications (Clavien-Dindo classification>Ⅱ) occurred in 2.6% of patients,and the most common late complications was gastroesophageal reflux disease,which could be relieved by acid suppressants. .Conclusion LSG is effective and safe in treating obesity and its co-morbidities.

Key words: obesity, laparoscopic sleeve gastrectomy, long-term weight loss, co-morbidities improvement, complications

CLC Number: